{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:13:54Z","timestamp":1781968434601,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.3816\/clm.2008.s.003","type":"journal-article","created":{"date-parts":[[2008,9,15]],"date-time":"2008-09-15T21:34:50Z","timestamp":1221514490000},"page":"S82-S88","source":"Crossref","is-referenced-by-count":25,"special_numbering":"S3","title":["Practical Management of Toxicities Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"8","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.003_bib1","first-page":"49","article-title":"Staging and prognosis in chronic myelogenous leukemia","volume":"25","author":"Sokal","year":"1988","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2008.s.003_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2008.s.003_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome [published erratum in: N Engl J Med 2001; 345:232]","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI- 571 inhibition of Abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.3816\/CLM.2008.s.003_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib9","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.003_bib10","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","article-title":"ARG tyrosine kinase activity is inhibited by STI571","volume":"97","author":"Okuda","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib11","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib12","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by ckit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3816\/CLM.2008.s.003_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published erratum in: Cancer Cell 2005; 7:399]","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2008.s.003_bib14","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.003_bib15","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin- 4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2008.s.003_bib16","first-page":"159","article-title":"BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum antitumor activities in vitro and in vivo","volume":"46","author":"Lee","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CLM.2008.s.003_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.3816\/CLM.2008.s.003_bib18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.003_bib20","doi-asserted-by":"crossref","first-page":"528a","DOI":"10.1182\/blood.V108.11.1862.1862","article-title":"A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL)","volume":"108","author":"Ottmann","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib21","first-page":"53a","article-title":"A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)","volume":"108","author":"le Coutre","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib22","doi-asserted-by":"crossref","first-page":"615a","DOI":"10.1182\/blood.V108.11.2169.2169","article-title":"A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib23","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib24","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib25","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.003_bib26","first-page":"358s","article-title":"Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.003_bib27","first-page":"613a","article-title":"Cytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (Sprycel\u00ae): clinical features and management, including outcome after hematopoietic growth factor therapy","volume":"108","author":"Quintas-Cardama","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib28","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte\u2013colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.003_bib29","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.003_bib30","unstructured":"Mauro M, Kurilik G, Balleisen S, et al. Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Paper presented at: the 43rd Annual Meeting of the American Society of Hematology; December 7\u201311, 2001; Orlando, FL. Abstract 584."},{"key":"10.3816\/CLM.2008.s.003_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.leukres.2003.11.003","article-title":"Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia","volume":"28","author":"Ault","year":"2004","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2008.s.003_bib32","doi-asserted-by":"crossref","first-page":"609a","DOI":"10.1182\/blood.V108.11.2148.2148","article-title":"The effect of interleukin-11 (oprelvekin, Neumega\u00ae) on thrombocytopenia associated with tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML)","volume":"108","author":"Aribi","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesisstimulating protein, for chronic ITP [published erratum in: N Engl J Med 2006; 355:2054]","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib34","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib35","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/cncr.20292","article-title":"Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase","volume":"100","author":"Cortes","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.003_bib36","first-page":"970","article-title":"Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells","volume":"1","author":"Kirschner","year":"2003","journal-title":"Mol Cancer Res"},{"key":"10.3816\/CLM.2008.s.003_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.003_bib38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec\u00ae)","volume":"19","author":"Fraunfelder","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.3816\/CLM.2008.s.003_bib39","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib40","first-page":"614a","article-title":"Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure","volume":"108","author":"Quintas-Cardama","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.003_bib41","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2008.s.003_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.\u2019","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"issue":"6 suppl","key":"10.3816\/CLM.2008.s.003_bib43","first-page":"ECR27","article-title":"Corticosteroids can reverse severe imatinib-induced hepatotoxicity","volume":"91","author":"Ferrero","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.003_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2008.s.003_bib45","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2002.03499.x","article-title":"Stevens-Johnson syndrome after treatment with STI571: a case report","volume":"117","author":"Hsiao","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.003_bib46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2141.2002.37133.x","article-title":"Sti571-induced Stevens-Johnson Syndrome","volume":"119","author":"Vidal","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.003_bib47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.3816\/CLM.2008.s.003_bib48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00277-007-0265-y","article-title":"Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose","volume":"86","author":"Mahapatra","year":"2007","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:38:22Z","timestamp":1588912702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":48,"alternative-id":["S1557919011702694"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.003","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}